Loading organizations...
SIGA Technologies develops and commercializes antiviral therapeutics to address critical unmet needs in global health security. The company's flagship product, TPOXX (tecovirimat), is an antiviral medication specifically designed and approved for the treatment of smallpox, alongside other orthopoxviruses. This medication has transitioned from early-stage research to a commercial entity, achieving FDA approvals for both oral and intravenous formulations.
The company was formally established on December 28, 1995, in New York City, with Dr. Donald P. D'Alessio serving as its first Chief Executive Officer. SIGA's foundational insight stemmed from a recognition of the growing need for countermeasures against serious infectious diseases and potential bioterrorism threats, positioning the firm to align its development efforts with national biodefense strategies from its inception.
SIGA's primary customers are government entities and strategic national stockpiles, including the U.S. Strategic National Stockpile, as well as international government procurements. The company envisions itself as a public health security powerhouse, maintaining an unwavering commitment to developing and delivering effective countermeasures for high-threat pathogens, thereby supporting global biodefense preparedness.
Siga has raised $910K across 1 funding round.
Siga has raised $910K in total across 1 funding round.
SIGA Technologies is a commercial-stage pharmaceutical company specializing in developing medicines to prevent and treat emerging infectious diseases, particularly orthopoxviruses such as smallpox and mpox (monkeypox). Its products serve governments, healthcare professionals, and global health organizations by providing critical countermeasures against highly infectious and deadly diseases that vaccines alone cannot fully address. SIGA’s flagship product, TPOXX, is a treatment for smallpox used by the U.S. Strategic National Stockpile and other global partners, reflecting its role in global health security. The company has demonstrated strong growth momentum with over $139 million in projected 2024 revenues and partnerships spanning more than 30 countries[1][2][3].
Founded with a mission to address urgent global health threats, SIGA Technologies has evolved into a leader in infectious disease treatment. The company’s leadership team comprises experts in infectious diseases and government relations, underscoring its focus on public health and security. SIGA’s idea emerged from the critical need to develop effective treatments for orthopoxviruses, which pose severe risks due to their infectiousness and lethality. Early pivotal moments include securing government contracts and establishing TPOXX as a key component of national biodefense strategies, particularly in the U.S., where it has been stockpiled for over a decade[1][2].
SIGA operates at the intersection of biotechnology and global health security, riding the trend of increased focus on pandemic preparedness and biodefense. The timing is critical as emerging infectious diseases and potential bioterrorism threats have heightened global awareness and funding for health security. Market forces such as government stockpiling programs, international cooperation on infectious disease control, and the limitations of vaccines alone create a favorable environment for SIGA’s products. By providing essential antiviral treatments, SIGA influences the broader ecosystem by strengthening global resilience against orthopoxvirus outbreaks and contributing to public health preparedness[1][2].
Looking ahead, SIGA is positioned to expand its portfolio and deepen its global partnerships as infectious disease threats evolve. Trends such as increased government investment in biodefense, advances in antiviral drug development, and heightened global health collaboration will shape its trajectory. SIGA’s influence may grow as it continues to innovate and respond to emerging pathogens, potentially broadening its impact beyond orthopoxviruses. Its commitment to proactive health security aligns with a future where preparedness and rapid response are paramount, reinforcing its role as a critical player in safeguarding public health worldwide[1][2].
Siga has raised $910K in total across 1 funding round.
Siga's investors include NewFund.
Siga has raised $910K across 1 funding round. Most recently, it raised $910K Seed in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $910K Seed | NewFund |